JP4845380B2 - サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン - Google Patents

サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン Download PDF

Info

Publication number
JP4845380B2
JP4845380B2 JP2004538405A JP2004538405A JP4845380B2 JP 4845380 B2 JP4845380 B2 JP 4845380B2 JP 2004538405 A JP2004538405 A JP 2004538405A JP 2004538405 A JP2004538405 A JP 2004538405A JP 4845380 B2 JP4845380 B2 JP 4845380B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004538405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503060A (ja
JP2006503060A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ピー． ドワイヤー，
ティモシー ジェイ． グジ，
カミル パルチ，
ロナルド ジェイ． ドール，
カルティック エム． キールティカー，
ヴィヨール エム． ギリジャバルラブハン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006503060A publication Critical patent/JP2006503060A/ja
Publication of JP2006503060A5 publication Critical patent/JP2006503060A5/ja
Application granted granted Critical
Publication of JP4845380B2 publication Critical patent/JP4845380B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004538405A 2002-09-19 2003-09-17 サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン Expired - Fee Related JP4845380B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41213802P 2002-09-19 2002-09-19
US60/412,138 2002-09-19
PCT/US2003/029841 WO2004026872A1 (en) 2002-09-19 2003-09-17 Pyrazolopyridines as cyclin dependent kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2006503060A JP2006503060A (ja) 2006-01-26
JP2006503060A5 JP2006503060A5 (cg-RX-API-DMAC7.html) 2006-10-19
JP4845380B2 true JP4845380B2 (ja) 2011-12-28

Family

ID=32030811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538405A Expired - Fee Related JP4845380B2 (ja) 2002-09-19 2003-09-17 サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン

Country Status (18)

Country Link
US (1) US7151104B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539750B1 (cg-RX-API-DMAC7.html)
JP (1) JP4845380B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050072090A (cg-RX-API-DMAC7.html)
CN (1) CN100475812C (cg-RX-API-DMAC7.html)
AR (1) AR041292A1 (cg-RX-API-DMAC7.html)
AT (1) ATE382048T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003270846B2 (cg-RX-API-DMAC7.html)
CA (1) CA2499593C (cg-RX-API-DMAC7.html)
DE (1) DE60318321T2 (cg-RX-API-DMAC7.html)
ES (1) ES2297203T3 (cg-RX-API-DMAC7.html)
IL (1) IL167432A (cg-RX-API-DMAC7.html)
MX (1) MXPA05003059A (cg-RX-API-DMAC7.html)
MY (1) MY136840A (cg-RX-API-DMAC7.html)
NZ (1) NZ538595A (cg-RX-API-DMAC7.html)
TW (1) TWI283243B (cg-RX-API-DMAC7.html)
WO (1) WO2004026872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502271B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101173510B1 (ko) 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
JP5117189B2 (ja) * 2004-08-27 2013-01-09 サイクラセル リミテッド プリン及びピリミジンｃｄｋ阻害剤、並びに自己免疫疾患の治療のためのそれらの使用
EP1859797A4 (en) * 2005-02-28 2011-04-13 Eisai R&D Man Co Ltd NEW SIMULTANEOUS USE OF A SULPHONAMIDE COMPOUND AND A MEDIUM AGAINST CANCER
DE602006021401D1 (de) * 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
AU2006234618A1 (en) * 2005-04-07 2006-10-19 Teijin Pharma Limited Pyrazolo(1,5-a)pyridine derivative or medically acceptable salt thereof
US7700773B2 (en) 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
EA018036B1 (ru) * 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US10550121B2 (en) * 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017087409A1 (en) 2015-11-18 2017-05-26 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
MX390117B (es) * 2016-09-07 2025-03-20 Haihe Biopharma Co Ltd Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011000A2 (en) * 1998-08-21 2000-03-02 Astrazeneca Ab New compounds
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
WO2002069968A1 (en) * 2001-03-08 2002-09-12 Astrazeneca Ab New use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091346B1 (en) * 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
JP2002508324A (ja) 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011000A2 (en) * 1998-08-21 2000-03-02 Astrazeneca Ab New compounds
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
WO2002069968A1 (en) * 2001-03-08 2002-09-12 Astrazeneca Ab New use

Also Published As

Publication number Publication date
AU2003270846B2 (en) 2006-11-23
MY136840A (en) 2008-11-28
WO2004026872A1 (en) 2004-04-01
CA2499593C (en) 2011-08-16
EP1539750A1 (en) 2005-06-15
JP2006503060A (ja) 2006-01-26
TW200409775A (en) 2004-06-16
ES2297203T3 (es) 2008-05-01
MXPA05003059A (es) 2005-05-27
AR041292A1 (es) 2005-05-11
CA2499593A1 (en) 2004-04-01
NZ538595A (en) 2006-04-28
ZA200502271B (en) 2005-09-19
DE60318321T2 (de) 2008-12-11
IL167432A (en) 2010-05-17
ATE382048T1 (de) 2008-01-15
AU2003270846A1 (en) 2004-04-08
KR20050072090A (ko) 2005-07-08
HK1071758A1 (en) 2005-07-29
TWI283243B (en) 2007-07-01
US7151104B2 (en) 2006-12-19
CN100475812C (zh) 2009-04-08
EP1539750B1 (en) 2007-12-26
US20040097516A1 (en) 2004-05-20
CN1681816A (zh) 2005-10-12
DE60318321D1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
JP4799864B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
JP4571969B2 (ja) キナーゼインヒビターとしてのピラゾロトリアジン
JP4790265B2 (ja) サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP4845743B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン誘導体
JP4700344B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006503838A (ja) サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
JP4845380B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502184A5 (cg-RX-API-DMAC7.html)
JP2011074088A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111011

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees